JP2016512216A - 主要電荷アイソフォームに富んだ抗体組成物を含む新規な薬剤 - Google Patents

主要電荷アイソフォームに富んだ抗体組成物を含む新規な薬剤 Download PDF

Info

Publication number
JP2016512216A
JP2016512216A JP2015562236A JP2015562236A JP2016512216A JP 2016512216 A JP2016512216 A JP 2016512216A JP 2015562236 A JP2015562236 A JP 2015562236A JP 2015562236 A JP2015562236 A JP 2015562236A JP 2016512216 A JP2016512216 A JP 2016512216A
Authority
JP
Japan
Prior art keywords
antibody
composition
monoclonal antibody
antibody composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015562236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512216A5 (https=
Inventor
ギヨーム・シュヴルー
ニコラ・ビオロー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB SA filed Critical LFB SA
Publication of JP2016512216A publication Critical patent/JP2016512216A/ja
Publication of JP2016512216A5 publication Critical patent/JP2016512216A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015562236A 2013-03-15 2014-03-14 主要電荷アイソフォームに富んだ抗体組成物を含む新規な薬剤 Pending JP2016512216A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1352360 2013-03-15
FR1352360A FR3003171B1 (fr) 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
PCT/EP2014/055179 WO2014140322A1 (fr) 2013-03-15 2014-03-14 Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Publications (2)

Publication Number Publication Date
JP2016512216A true JP2016512216A (ja) 2016-04-25
JP2016512216A5 JP2016512216A5 (https=) 2017-04-06

Family

ID=48771615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562236A Pending JP2016512216A (ja) 2013-03-15 2014-03-14 主要電荷アイソフォームに富んだ抗体組成物を含む新規な薬剤

Country Status (11)

Country Link
US (1) US20160046722A1 (https=)
EP (1) EP2968533A1 (https=)
JP (1) JP2016512216A (https=)
KR (1) KR20150132522A (https=)
CN (1) CN105163758B (https=)
AU (1) AU2014230134A1 (https=)
BR (1) BR112015023209A8 (https=)
CA (1) CA2907358A1 (https=)
FR (1) FR3003171B1 (https=)
MX (1) MX2015012812A (https=)
WO (1) WO2014140322A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533245A (ja) * 2019-05-23 2022-07-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体のドメイン特異的電荷変異体の特徴付け

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2729496B8 (en) 2011-07-06 2017-10-18 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
AU2017261142B2 (en) 2016-05-04 2022-03-10 Delaval Holding Ab A cartridge for a teatcup, and a teatcup
FR3053688A1 (fr) * 2016-07-06 2018-01-12 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Mutants fc a activite fonctionnelle amelioree
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
CN113614107A (zh) 2019-01-23 2021-11-05 Encefa公司 Cd31竞争剂及其用途
CN114829407B (zh) * 2019-09-23 2024-06-21 南开大学 利用哺乳动物展示筛选FcγR特异性结合Fc
WO2023041717A1 (en) 2021-09-16 2023-03-23 Aboleris Pharma Anti-human cd45rc binding domains and uses thereof
CN114236010A (zh) * 2021-12-18 2022-03-25 苏州莱奥生物技术有限公司 一种生物活性药物的药代动力学分析方法
CN115073548A (zh) * 2022-08-01 2022-09-20 上海蓝析生物技术有限公司 一种用于重组蛋白药物电荷异构体制备的缓冲体系

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512019A (ja) * 1999-01-15 2003-04-02 ジェネンテック・インコーポレーテッド 変化したエフェクター機能を有するポリペプチド変異体
JP2003534781A (ja) * 2000-04-12 2003-11-25 ラボラトワール、フランセ、デュ、フラクショヌマン、エ、デ、ビオテクノロジ 抗ｄモノクローナル抗体
JP2006507844A (ja) * 2002-10-17 2006-03-09 ゲンマブ エー／エス Ｃｄ２０に対するヒトモノクローナル抗体
JP2006512407A (ja) * 2002-09-27 2006-04-13 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体およびそれらの生成方法
JP2006516951A (ja) * 2002-09-13 2006-07-13 ラボラトワール フランセ デュ フラクションヌメント エ デ バイオテクノロジーズ Ａｄｃｃおよびサイトカイン産生の誘導のための抗体
JP2006524039A (ja) * 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
JP2007533639A (ja) * 2003-10-16 2007-11-22 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジー 強い食作用活性を有するＹＢ２／０細胞株の抗ＲＨＥＳＵＳ−ＤＩｇＧ３
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567976B1 (en) * 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512019A (ja) * 1999-01-15 2003-04-02 ジェネンテック・インコーポレーテッド 変化したエフェクター機能を有するポリペプチド変異体
JP2003534781A (ja) * 2000-04-12 2003-11-25 ラボラトワール、フランセ、デュ、フラクショヌマン、エ、デ、ビオテクノロジ 抗ｄモノクローナル抗体
JP2006516951A (ja) * 2002-09-13 2006-07-13 ラボラトワール フランセ デュ フラクションヌメント エ デ バイオテクノロジーズ Ａｄｃｃおよびサイトカイン産生の誘導のための抗体
JP2006512407A (ja) * 2002-09-27 2006-04-13 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体およびそれらの生成方法
JP2006507844A (ja) * 2002-10-17 2006-03-09 ゲンマブ エー／エス Ｃｄ２０に対するヒトモノクローナル抗体
JP2006524039A (ja) * 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
JP2007533639A (ja) * 2003-10-16 2007-11-22 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジー 強い食作用活性を有するＹＢ２／０細胞株の抗ＲＨＥＳＵＳ−ＤＩｇＧ３
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MABS, vol. 2, no. 6, JPN6017047126, 2010, pages 613 - 624, ISSN: 0003698067 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533245A (ja) * 2019-05-23 2022-07-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体のドメイン特異的電荷変異体の特徴付け

Also Published As

Publication number Publication date
EP2968533A1 (fr) 2016-01-20
BR112015023209A8 (pt) 2018-01-23
FR3003171B1 (fr) 2015-04-10
CA2907358A1 (fr) 2014-09-18
FR3003171A1 (fr) 2014-09-19
WO2014140322A1 (fr) 2014-09-18
US20160046722A1 (en) 2016-02-18
CN105163758B (zh) 2017-11-17
BR112015023209A2 (pt) 2017-07-18
MX2015012812A (es) 2016-05-09
AU2014230134A1 (en) 2015-10-29
CN105163758A (zh) 2015-12-16
KR20150132522A (ko) 2015-11-25

Similar Documents

Publication Publication Date Title
CN105163758B (zh) 包含富集主要电荷同工型的抗体组合物的药物
TWI732176B (zh) 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
Jefferis Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action
US20200277385A1 (en) Anti-CD303 Monoclonal Antibodies
CN106519025B (zh) 利用cdr的氨基酸取代来改变抗体等电点的方法
Shibata-Koyama et al. The N-linked oligosaccharide at FcγRIIIa Asn-45: an inhibitory element for high FcγRIIIa binding affinity to IgG glycoforms lacking core fucosylation
Jung et al. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity
CN115942976A (zh) 掩蔽的il-2细胞因子和其切割产物
EP4214240B1 (en) Anti-ccr8 antibodies
HK1252829A1 (zh) 促进抗原消除的抗原结合分子
ES2619677T3 (es) Método de separación para anticuerpos fucosilados
EP4206223A1 (en) Heterodimer fc polypeptide
CN105392878A (zh) 用于控制蛋白质中的岩藻糖基化水平的方法
JP2022514734A (ja) 抗ｔｒｅｍ２抗体の使用方法
Wang et al. The interplay of protein engineering and glycoengineering to fine‐tune antibody glycosylation and its impact on effector functions
CN111479618A (zh) 用于表征药物产品杂质的系统和方法
TWI920354B (zh) 抗ｃｃｒ８抗體
RU2838581C2 (ru) Антигенсвязывающая молекула, содержащая два антигенсвязывающих домена, которые связаны друг с другом
BR122024013309A2 (pt) Anticorpos anti-ccr8 e composição compreendendo os mesmos
HK40100657A (en) Anti-ccr8 antibodies
HK40100657B (en) Anti-ccr8 antibodies
HK40085483A (en) Heterodimer fc polypeptide
HK40034272B (en) Fully human anti-b cell maturation antigen (bcma) single chain variable fragment, and application thereof
BR112019010485B1 (pt) Método para a produção de um anticorpo
HK1232553A (en) Method of modifying isoelectric point of antibody via amino acid substitution in cdr

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180713